Actinium Seeks to Disrupt As Radioligand Candidate Succeeds In Pivotal Pre-Transplant AML Trial

 
• By Ayisha Sharma

The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.    

Sign for Radioactivity
Radioligands Combine A Tumor-Targeting Molecule With A Radioactive Atom • Source: Shutterstock

More from Clinical Trials

More from R&D